Research News and Research

RSS

Amedica announces US Spine acquisition

Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has acquired US Spine, a privately held, well-known medical device company focused on the development and commercialization of advanced spinal implant systems.

21 Sep 2010

New genes associated with osteoarthritis progression

Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced today findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

National survey highlights need for greater awareness on lymphoma

While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma.

21 Sep 2010

First Edition: September 21, 2010

In today's headlines, news about major insurers' plans to stop offering child-only health policies in advance of new rules.

21 Sep 2010

For-profit clinics charge patients unlawful user fees for health services already covered by Medicare

New research conducted by the BC Health Coalition has revealed evidence that for-profit clinics across the province continue to openly charge patients additional fees to jump the queue for health services already covered by Medicare.

21 Sep 2010

ADI releases World Alzheimer Report 2010

The World Alzheimer Report 2010 was released today to mark World Alzheimer's Day and heighten awareness of the global economic impact of Alzheimer's disease and related dementias.

21 Sep 2010

NIGMS director wins 2011 ASBMB Public Service Award

The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.

21 Sep 2010

Florida institutions to host oil spill research conference

The University of South Florida, Florida Institute of Oceanography, Mote Marine Laboratory, and the State of Florida Oil Spill Academic Task Force will host a major oil spill research conference, February 9-11, 2011, at the Hilton St. Petersburg Bayfront in St. Petersburg, Florida.

21 Sep 2010

immatics raises EUR53.8million in Series C financing round

immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics' existing pipeline of advanced therapeutic cancer vaccine candidates.

21 Sep 2010

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

The University of Maryland School of Pharmacy has received a prestigious $3.7 million grant to develop a drug to treat cocaine addiction based on an active ingredient found in some Chinese prescription medicines.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

ImmunoGen commences clinical testing with SAR566658 anticancer compound

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.

21 Sep 2010

ASM awards UTHealth student 3-year, $33,000 fellowship for study of molecular details of protein folding in cells

Jennifer Abrams, a graduate student at The University of Texas Health Science Center at Houston (UTHealth), has been awarded a three-year, $33,000 fellowship from the American Society for Microbiology (ASM) to support her innovative research into the molecular causes of protein misfolding diseases like Alzheimer's, Lou Gehrig's and Parkinson's.

21 Sep 2010

Study says PTSD veterans suffer from more medical conditions

Is the US health system comprehensively meeting the needs of returning veterans? With the recent attention to mental illness in returning soldiers, and post traumatic stress disorder (PTSD) in particular, little research has focused on the medical care needs of those returning from Operation Enduring Freedom/Operation Iraqi Freedom, according to Dr. Susan Frayne, from the VA Palo Alto Health Care System and Stanford University, and colleagues.

21 Sep 2010

Paper highlights need for new studies and guidelines around oxygen therapy during MI

The European Society of Cardiology (ESC) welcomes a paper published today in the Journal of the American College of Cardiology (JACC )(1) highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

21 Sep 2010

Social exclusion induces people to spend money and consume in service of affiliation

People who feel excluded will go to any length to try to become part of a group, even if it involves spending large sums of cash, eating something dicey, or doing illicit drugs, according to a new study in the Journal of Consumer Research.

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Recession leads to closure of long-term care facilities: Study

The 2008-2009 recession led to smaller cost increases at many long-term care facilities and forced some to close altogether, according to a study released today by Prudential Financial Inc. (NYSE). The bi-annual report, 2010 Long-Term Care Cost Study, measures trends in costs associated with the major forms of long-term care services. And, for the first time, the research includes consumer views that measure sentiment around the cost of services and levels of awareness and concern about the future need for long-term care and how to fund it.

21 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010